Sven-Erik Strand
11 – 20 of 184
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
A 3D-printed mouse phantom for the evaluation of a hand-held CZT-based gamma camera
(2022) 2022 Höstmöte för Cancerfondens Planeringsgrupp för Onkologisk Radionuklidterapi
- Contribution to conference › Abstract
- 2021
-
Mark
PSA-Targeted Alpha-, Beta-, and Positron-emitting immunotheranostics in murine prostate cancer models and nonhuman primates
- Contribution to journal › Article
-
Mark
Kidney protection with the radical scavenger α1-microglobulin (A1m) during peptide receptor radionuclide and radioligand therapy
- Contribution to journal › Article
-
Mark
A conjugation strategy to modulate antigen binding and FcRn interaction leads to improved tumor targeting and radioimmunotherapy efficacy with an antibody targeting prostate-specific antigen
- Contribution to journal › Article
-
Mark
177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging
- Contribution to journal › Article
-
Mark
Humanization, radiolabeling and biodistribution studies of an igg1-type antibody targeting uncomplexed psa for theranostic applications
- Contribution to journal › Article
- 2020
-
Mark
Quantitative γ-H2AX immunofluorescence method for DNA double-strand break analysis in testis and liver after intravenous administration of 111InCl3
- Contribution to journal › Article
-
Mark
Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy
(2020) In Proceedings of the National Academy of Sciences of the United States of America 117(26). p.15172-15181
- Contribution to journal › Article
- 2019
-
Mark
Harnessing androgen receptor pathway activation for targeted alpha particle radioimmunotherapy of breast cancer
- Contribution to journal › Article
-
Mark
Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics
- Contribution to journal › Article
